
The FDA has given the green light to Novartis’ new heart failure drug, six weeks ahead of the scheduled date …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

